Role of Serum Prostatic Acid Phosphatase on Prostate Cancer Patients

Abstract

Author(s): Jinseog Kim, Mahashweta Das, Ishita Saha, Gaurab Bhattacharyya, Sabyasachi Mukherjee, Ranjan Kumar Sahoo, Rajyalakshmi Kottapalli, Rajkumari Sanatombi Devi, Sunit Kumar Medda and Rabindra Nath Das*

It is well known that serum prostatic acid phosphatase (SPAP) may have a great role on Prostate Cancer Patients (PCPs), but its effects are not clearly identified in the prostate cancer literature. The current article aims to identify the effects of SPAP on PCPs. It is derived herein that mean SPAP level is higher for PCPs (P<0.0001) and PCPs confined to bed (P=0.0794) than normal. Mean SPAP level is higher for PCPs with Bone Metastases (BM) (P<0.0001), and it is lower for cardiovascular disease history patients (CDHPs) (P=0.0188) than normal. Mean SPAP level is positively connected with estrogen level (P=0.1148) in the log-normal fitted model, while it is highly significant (P<0.0001) in the gamma fitted model. In addition, mean SPAP level is positively related with Serum Hemoglobin (SHG) (P=0.0167), size of primary tumor (P=0.0092) and study time (P=0.0463). Variance of SPAP level is higher scattered for PCPs (P<0.0001), and PCPs with BM (P=0.0005), or CDHPs (P=0.0113) than normal. Again, variance of SPAP level is positively related with diastolic blood pressure (DBP) (P=0.0433), estrogen level (P=0.0225), size of primary tumor (SZ) (P=0.0915) and index of tumor stage and histolic grade (SG) (P=0.0155), while it is negatively connected with electrocardiogram status (P=0.0229) and SHG (P=0.0340). The report concludes that SPAP is highly associated with PCPs and along with their many factors such as SHG, estrogen level, BM, size of primary tumor, DBP etc.

Share this article